MAPLE GROVE, Minnesota, December 7, 2009- r4 Vascular, a Minnesota-based
medical device company best known for its PegasusTM, ZeusTM, and DrainExTM
catheter brands, has announced the FDA’s clearance of its power-injectable
PherociousTM Apheresis Catheter. It is the first apheresis catheter that, in addition to
apheresis, intravenous infusions, and blood sampling, is indicated for power injection
of contrast media for contrast enhanced computed tomography (CECT) imaging. The
catheter will be available in both 12.5F and 10.5F sizes.
According to r4 Vascular’s VP Sales, Ehab Ali, “The added functionality of our
Pherocious catheter will reduce the number of needlesticks apheresis patients
currently require for CT studies.” He goes on to say, “There have been few
innovations in vascular access for apheresis patients, and r4 is proud to be able to
help these patients with our new triple lumen catheter.”
According to Patricia Golden, RN, and Hemapheresis Practitioner (ASCP), “More
than a quarter of a million patients undergo apheresis each year for the treatment of
neurological, immunologic, hematologic or oncologic disorders; and for stem cell
transplantation.”
r4 Vascular is a privately-held vascular access company driving innovation in vascular
access medical technology. r4's passion is “uncomplicating” venous access,
chemotherapy, and drug delivery, through product improvements that help catheters
remain patent and effective, with reduced risk of complications. The Pherocious
apheresis catheter is the 4th new catheter launched by r4 Vascular this year.
